Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Payables (2016 - 2025)

Haemonetics has reported Payables over the past 16 years, most recently at $48.7 million for Q4 2025.

  • For Q4 2025, Payables fell 22.7% year-over-year to $48.7 million; the TTM value through Dec 2025 reached $48.7 million, down 22.7%, while the annual FY2025 figure was $67.0 million, 8.67% down from the prior year.
  • Payables for Q4 2025 was $48.7 million at Haemonetics, down from $61.7 million in the prior quarter.
  • Over five years, Payables peaked at $80.2 million in Q3 2023 and troughed at $45.0 million in Q4 2021.
  • A 5-year average of $61.1 million and a median of $61.6 million in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: soared 36.73% in 2022 and later tumbled 40.19% in 2025.
  • Year by year, Payables stood at $45.0 million in 2021, then skyrocketed by 41.81% to $63.8 million in 2022, then decreased by 10.86% to $56.8 million in 2023, then grew by 10.81% to $63.0 million in 2024, then decreased by 22.7% to $48.7 million in 2025.
  • Business Quant data shows Payables for HAE at $48.7 million in Q4 2025, $61.7 million in Q3 2025, and $46.0 million in Q2 2025.